Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor

Transplantation

Volumn 86, Issue 11, 2008, Pages 1523-1530

  Schmidt, Peter ^a   Magnusson, Caroline ^a   Lundgren, Torbjörn ^b   Korsgren, Olle ^c   Nilsson, Bo ^c  

^a Karlsfältsvägen   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1; DEXTRAN SULFATE; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT DEXTRAN SULFATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; SIGNAL PEPTIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FEMALE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NORMAL HUMAN; PANCREAS ISLET; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; BLEEDING; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; THROMBOCYTE COUNT; TIME;

ADULT; DEXTRAN SULFATE; FEMALE; GENE EXPRESSION REGULATION; HEMORRHAGE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; TIME FACTORS;

EID: 58149331125     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181890593     Document Type: Article

References (28)

1. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 1907.
2. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039.
3. Berman DM, Cabrera O, Kenyon NM, et al. Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation 2007; 84: 308.
4. Johansson H, Goto M, Dufrane D, et al. Low molecular weight dextran sulfate: A strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006; 6: 305.
5. Fiorante P, Banz Y, Mohacsi PJ, et al. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. Xenotransplantation 2001; 8: 24.
6. Laumonier T, Mohacsi PJ, Matozan KM, et al. Endothelial cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. Am J Transplant 2004; 4: 181.
7. Thomas H, Maillet F, Letourneur D, et al. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol Immunol 1996; 33: 643.
8. Bos IG, van Mierlo GJ, Bleeker WK, et al. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: Studies in a rat model. Int Immunopharmacol 2001; 1: 1583.
9. Wuillemin WA, te Velthuis H, Lubbers YT, et al. Potentiation of C1 inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997; 159: 1953.
10. Ley K, Allietta M, Bullard DC, et al. Importance of E-selectin for firm leukocyte adhesion in vivo. Circ Res 1998; 83: 287.
11. Matsumiya A, Yamaguchi M, Nakano H, et al. Dextran sulfate inhibits E-selectin-mediated neutrophil adhesion to endotoxin-activated vascular endothelial cells. Life Sci 1999; 64: PL9.
12. Hagiwara A, Sawai K, Sakakura C, et al. Prevention of peritoneal metastasis of cancer with dextran sulfate - An experimental study in mice. Anticancer Drugs 1997; 8: 894.
13. Abrams DI, Kuno S, Wong R, et al. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110: 183.
14. Flexner C, Barditch-Crovo PA, Kornhauser DM, et al. Pharmacokinet-ics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2544.
15. Fujishima M, Omae T, Tanaka K, et al. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 1986; 37: 487.
16. Hiebert LM, Wice SM, Jaques LB, et al. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J Lab Clin Med 1999; 133: 161.
17. Lorentsen KJ, Hendrix CW, Collins JM, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989; 111: 561.
18. Zioncheck TF, Richardson L, Liu J, et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 1995; 270: 16871.
19. Nakano M, Yasunami Y, Maki T, et al. Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts. Transplantation 2000; 69: 214.
20. Sanchez J, Elgue G, Riesenfeld J, et al. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 1998; 89: 41.
21. Nilsson Ekdahl K, Nilsson B, Pekna M, et al. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992; 35: 85.
22. Mollnes TE, Riesenfeld J, Garred P, etal. A new model for evaluation of biocompatibility: Combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 1995; 19: 909.
23. Hedin H, Richter W, Messmer K, et al. Incidence, pathomechanism and prevention of dextran-induced anaphylactoid/anaphylactic reactions in man. Dev Biol Stand 1980; 48: 179.
24. Gahr S, Merger M, Bollheimer LC, et al. Hepatocyte growth factor stimulates proliferation of pancreatic beta-cells particularly in the presence of subphysiological glucose concentrations. J Mol Endocrinol 2002; 28: 99.
25. Garcia-Ocana A, Takane KK, Reddy VT, et al. Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic islet transplant performance and reduces beta cell death. J Biol Chem 2003; 278: 343.
26. Garcia-Ocana A, Vasavada RC, Cebrian A, et al. Transgenic overex-pression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes 2001; 50: 2752.
27. Lopez-Talavera JC, Garcia-Ocana A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: Reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145: 467.
28. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepa-tocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94: 701.